What is a stock summary page? Click here for an overview.
Business Description
Enovis Corp
NAICS : 339112
SIC : 3845
ISIN : US1940145022
Share Class Description:
LTS:0I1B: Ordinary SharesDescription
Enovis Corp is a medical technology company that offers medical devices and services across the continuum of patient care, from injury prevention to joint replacement to rehabilitation after surgery, injury, or degenerative disease. Its reportable segments are Prevention & Recovery (P&R) and Reconstructive (Recon). The company generates the maximum revenue from the Prevention & Recovery segment, which includes products that are used to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports-related injuries. The Reconstructive segment provides a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and surgical productivity tools. Geographically, it derives key revenue from the U.S.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.03 | |||||
| Equity-to-Asset | 0.54 | |||||
| Debt-to-Equity | 0.55 | |||||
| Debt-to-EBITDA | -2.92 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 0.58 | |||||
| Beneish M-Score | -2.78 | |||||
| WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 11 | |||||
| 3-Year Book Growth Rate | -19.7 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 14.17 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 6.11 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 36.84 | |||||
| 9-Day RSI | 40.92 | |||||
| 14-Day RSI | 40.66 | |||||
| 3-1 Month Momentum % | -12.41 | |||||
| 6-1 Month Momentum % | -9.25 | |||||
| 12-1 Month Momentum % | -38.31 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.17 | |||||
| Quick Ratio | 1.13 | |||||
| Cash Ratio | 0.09 | |||||
| Days Inventory | 222.63 | |||||
| Days Sales Outstanding | 64.93 | |||||
| Days Payable | 61.84 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2.4 | |||||
| Shareholder Yield % | -44.98 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 56.02 | |||||
| Operating Margin % | -4.91 | |||||
| Net Margin % | -39.17 | |||||
| FCF Margin % | -3.19 | |||||
| ROE % | -25.95 | |||||
| ROA % | -16.06 | |||||
| ROIC % | -2.2 | |||||
| 3-Year ROIIC % | 1.79 | |||||
| ROC (Joel Greenblatt) % | -73.99 | |||||
| ROCE % | -16.5 | |||||
| Years of Profitability over Past 10-Year | 6 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 11.69 | |||||
| PE Ratio without NRI | 31.09 | |||||
| PS Ratio | 1 | |||||
| PB Ratio | 0.83 | |||||
| Price-to-Operating-Cash-Flow | 18.81 | |||||
| EV-to-EBIT | -4.54 | |||||
| EV-to-Forward-EBIT | 12.32 | |||||
| EV-to-EBITDA | -7.23 | |||||
| EV-to-Forward-EBITDA | 8.47 | |||||
| EV-to-Revenue | 1.65 | |||||
| EV-to-Forward-Revenue | 1.56 | |||||
| EV-to-FCF | -52.59 | |||||
| Price-to-GF-Value | 0.55 | |||||
| Price-to-Projected-FCF | 0.84 | |||||
| Price-to-Median-PS-Value | 1 | |||||
| Earnings Yield (Greenblatt) % | -22.02 | |||||
| FCF Yield % | -3.25 | |||||
| Forward Rate of Return (Yacktman) % | -17.54 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Enovis Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 2,107.623 | ||
| EPS (TTM) ($) | -14.29 | ||
| Beta | 1.04 | ||
| 3-Year Sharpe Ratio | -0.68 | ||
| 3-Year Sortino Ratio | -0.88 | ||
| Volatility % | 33.53 | ||
| 14-Day RSI | 40.66 | ||
| 14-Day ATR ($) | 0.624219 | ||
| 20-Day SMA ($) | 37.975405 | ||
| 12-1 Month Momentum % | -38.31 | ||
| 52-Week Range ($) | 35.5093 - 62.29 | ||
| Shares Outstanding (Mil) | 56.96 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Enovis Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Enovis Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Enovis Corp Frequently Asked Questions
What is Enovis Corp(LTS:0I1B)'s stock price today?
The current price of LTS:0I1B is $37.93. The 52 week high of LTS:0I1B is $62.29 and 52 week low is $35.51.
When is next earnings date of Enovis Corp(LTS:0I1B)?
The next earnings date of Enovis Corp(LTS:0I1B) is 2025-05-02 Est..
Does Enovis Corp(LTS:0I1B) pay dividends? If so, how much?
Enovis Corp(LTS:0I1B) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers